Aj. Eherer et al., EFFECT OF 5-HYDROXYTRYPTAMINE ANTAGONISTS ON CHOLERA TOXIN-INDUCED SECRETION IN THE HUMAN JEJUNUM, European journal of clinical investigation, 24(10), 1994, pp. 664-668
In rats, the combined administration of the 5-HT2 antagonist ketanseri
n and the 5-HT3 antagonist tropisetron inhibits cholera toxin-induced
intestinal secretion. We investigated whether these agents and the 5-H
T3 antagonist ondansetron can inhibit cholera toxin-induced secretion
in the human jejunum using a segmental perfusion technique. In a first
control period the subjects' jejunums were perfused continuously with
a plasma-like electrolyte solution. In a second control period they e
ither received a combination of tropisetron plus ketanserin, or tropis
etron or ondansetron alone. Cholera toxin 6.25 mu g was then administe
red intrajejunally and the experiments were continued for 4 h. Net wat
er movements during the 4th hour after CT administration minus net wat
er movement during the first control period was used for further calcu
lation and was referred to as net luminal gain. In perfusion studies w
ith tropisetron plus ketanserin resp. ondansetron the net luminal gain
of water (+161 +/- 26 resp. 189 +/- 28 ml 30 cm(-1) h(-1), mean +/- S
EM) was significantly higher compared to perfusion studies with choler
a toxin alone (+94 +/- 30). Treatment with tropisetron did not change
the CT-induced net luminal gain of water (+108 +/- 41). Movements of s
odium, chloride, bicarbonate and potassium paralleled the movement of
water. In agreement with these observations we found a deterioration o
f clinical parameters after the end of the perfusion studies in four o
f five subjects treated with CT 25 mu g plus ketanserin and tropisetro
n. Contrary to what has been observed in animal experiments the result
s in humans indicate enhancement rather than inhibition of CT-induced
secretion by administration of 5-HT antagonists. Our results do not su
pport the contention that the intravenous administration of ketanserin
, tropisetron or ondansetron might be of potential therapeutic value i
n patients with Asiatic cholera.